Human Osteoprotegerin ELISA Kit (ab100617)
Key features and details
- Sensitivity: 1 pg/ml
- Range: 1.23 pg/ml - 900 pg/ml
- Sample type: Cell culture supernatant, Cell Lysate, Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Human Osteoprotegerin ELISA Kit
See all Osteoprotegerin kits -
Detection method
Colorimetric -
Sample type
Cell culture supernatant, Serum, Plasma, Cell Lysate -
Assay type
Sandwich (quantitative) -
Sensitivity
< 1 pg/ml -
Range
1.23 pg/ml - 900 pg/ml -
Recovery
100 %
Sample specific recovery Sample type Average % Range Cell culture supernatant 99.75 89% - 108% Serum 99.85 89% - 108% Plasma 102.45 90% - 109% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Abcam’s Osteoprotegerin Human ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human Osteoprotegerin in serum, plasma, and cell culture supernatants.
This assay employs an antibody specific for Human Osteoprotegerin coated on a 96-well plate. Standards and samples are pipetted into the wells and Osteoprotegerin present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human Osteoprotegerin antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Osteoprotegerin bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Get results in 90 minutes with Human Osteoprotegerin ELISA Kit (ab189580) from our SimpleStep ELISA® range.
Produced using a non-baculovirus expression system.
-
Notes
Optimization may be required with urine samples.
We recommend preparing serum-free or low-serum medium samples, as serum tends to contain cytokines which may produce significant background signals. If it is necessary to test serum-containing medium, we recommend also running an uncultured media blank to assess baseline signals. This baseline can then be subtracted from the cultured media sample data.
-
Platform
Microplate
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 1 x 96 tests 20X Wash Buffer 1 x 25ml 5X Assay Diluent B 1 x 15ml 500X HRP-Streptavidin Concentrate 1 x 200µl Assay Diluent A 1 x 30ml Biotinylated anti-Human Osteoprotegerin 2 vials Osteoprotegerin Microplate (12 x 8 wells) 1 unit Recombinant Human Osteoprotegerin Standard (lyophilized) 2 vials Stop Solution 1 x 8ml TMB One-Step Substrate Reagent 1 x 12ml -
Research areas
-
Function
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. -
Tissue specificity
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. -
Involvement in disease
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal. -
Sequence similarities
Contains 2 death domains.
Contains 4 TNFR-Cys repeats. -
Post-translational
modificationsN-glycosylated. Contains sialic acid residues.
The N-terminus is blocked. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- MGC29565
- OCIF
- OPG
see all -
Database links
- Entrez Gene: 4982 Human
- Omim: 602643 Human
- SwissProt: O00300 Human
- Unigene: 81791 Human
Associated products
-
SimpleStep ELISA kits
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (15)
ab100617 has been referenced in 15 publications.
- Lee YS et al. Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates. Korean J Intern Med 37:821-829 (2022). PubMed: 35468703
- Fernández-Lizárraga M et al. Evaluation of the Biocompatibility and Osteogenic Properties of Metal Oxide Coatings Applied by Magnetron Sputtering as Potential Biofunctional Surface Modifications for Orthopedic Implants. Materials (Basel) 15:N/A (2022). PubMed: 35955174
- Ounjaijean S et al. Cardiovascular risks in Asian HIV-infected patients receiving boosted-protease inhibitor-based antiretroviral treatment. J Infect Dev Ctries 15:289-296 (2021). PubMed: 33690213
- Gaude E et al. A Novel Combination of Blood Biomarkers and Clinical Stroke Scales Facilitates Detection of Large Vessel Occlusion Ischemic Strokes. Diagnostics (Basel) 11:N/A (2021). PubMed: 34206615
- Lai WY et al. Synergies of Human Umbilical Vein Endothelial Cell-Laden Calcium Silicate-Activated Gelatin Methacrylate for Accelerating 3D Human Dental Pulp Stem Cell Differentiation for Endodontic Regeneration. Polymers (Basel) 13:N/A (2021). PubMed: 34641117